1
|
Lugli F, Sciutto G, Oliveri P, Malegori C, Prati S, Gatti L, Silvestrini S, Romandini M, Catelli E, Casale M, Talamo S, Iacumin P, Benazzi S, Mazzeo R. Near-infrared hyperspectral imaging (NIR-HSI) and normalized difference image (NDI) data processing: An advanced method to map collagen in archaeological bones. Talanta 2021; 226:122126. [PMID: 33676680 DOI: 10.1016/j.talanta.2021.122126] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Revised: 01/13/2021] [Accepted: 01/15/2021] [Indexed: 12/28/2022]
Abstract
In the present study, an innovative and highly efficient near-infrared hyperspectral imaging (NIR-HSI) method is proposed to provide spectral maps able to reveal collagen distribution in large-size bones, also offering semi-quantitative estimations. A recently introduced method for the construction of chemical maps, based on Normalized Difference Images (NDI), is declined in an innovative approach, through the exploitation of the NDI values computed for each pixel of the hyperspectral image to localize collagen and to extract information on its content by a direct comparison with known reference samples. The developed approach addresses an urgent issue of the analytical chemistry applied to bioarcheology researches, which rely on well-preserved collagen in bones to obtain key information on chronology, paleoecology and taxonomy. Indeed, the high demand for large-sample datasets and the consequent application of a wide variety of destructive analytical methods led to the considerable destruction of precious bone samples. NIR-HSI pre-screening allows researchers to properly select the sampling points for subsequent specific analyses, to minimize costs and time and to preserve integrity of archaeological bones (which are available in a very limited amount), providing further opportunities to understand our past.
Collapse
Affiliation(s)
- F Lugli
- University of Bologna, Department of Cultural Heritage, Ravenna Campus, Via Degli Ariani, 1, 48121, Ravenna, Italy
| | - G Sciutto
- University of Bologna, Department of Chemistry "G. Ciamician", Ravenna Campus, Via Guaccimanni, 42, 48121, Ravenna, Italy.
| | - P Oliveri
- University of Genova, Department of Pharmacy, Viale Cembrano 4, I-16148, Genova, Italy.
| | - C Malegori
- University of Genova, Department of Pharmacy, Viale Cembrano 4, I-16148, Genova, Italy
| | - S Prati
- University of Bologna, Department of Chemistry "G. Ciamician", Ravenna Campus, Via Guaccimanni, 42, 48121, Ravenna, Italy
| | - L Gatti
- University of Bologna, Department of Chemistry "G. Ciamician", Ravenna Campus, Via Guaccimanni, 42, 48121, Ravenna, Italy
| | - S Silvestrini
- University of Bologna, Department of Cultural Heritage, Ravenna Campus, Via Degli Ariani, 1, 48121, Ravenna, Italy
| | - M Romandini
- University of Bologna, Department of Cultural Heritage, Ravenna Campus, Via Degli Ariani, 1, 48121, Ravenna, Italy
| | - E Catelli
- University of Bologna, Department of Chemistry "G. Ciamician", Ravenna Campus, Via Guaccimanni, 42, 48121, Ravenna, Italy
| | - M Casale
- University of Genova, Department of Pharmacy, Viale Cembrano 4, I-16148, Genova, Italy
| | - S Talamo
- University of Bologna, Department of Chemistry "G. Ciamician", Via Selmi, 2, 40126, Bologna, Italy; Department of Human Evolution, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany
| | - P Iacumin
- University of Parma, Department of Chemistry, Life Sciences and Environmental Sustainability, Parco Area Delle Scienze, 11/a, Parma, Italy
| | - S Benazzi
- University of Bologna, Department of Cultural Heritage, Ravenna Campus, Via Degli Ariani, 1, 48121, Ravenna, Italy; Department of Human Evolution, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany
| | - R Mazzeo
- University of Bologna, Department of Chemistry "G. Ciamician", Ravenna Campus, Via Guaccimanni, 42, 48121, Ravenna, Italy
| |
Collapse
|
3
|
Iacovazzo D, Bianchi A, Lugli F, Milardi D, Giampietro A, Lucci-Cordisco E, Doglietto F, Lauriola L, De Marinis L. Double pituitary adenomas. Endocrine 2013; 43:452-7. [PMID: 23325364 DOI: 10.1007/s12020-013-9876-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Accepted: 01/07/2013] [Indexed: 10/27/2022]
Abstract
Double pituitary adenomas represent up to 2.6 % of pituitary adenomas in large surgical series and up to 3.3 % of patients with Cushing's disease have been found to have double or multiple pituitary adenomas. We report the case of a 60-year-old male patient whose medical history began in 2002 with erectile dysfunction; hyperprolactinemia was found and MRI showed a 6-mm area of delayed enhancement in the lateral portion of the right pituitary lobe. Treatment with cabergoline was started with normalization of prolactin levels; the following MRI, performed in 2005 and 2008, showed shrinkage of the pituitary lesion. In 2005, the patient began to manifest weight gain, hypertension, and facial plethora, but no further evaluations were done. In January 2010, the patient came to our attention and underwent multiple tests that suggested Cushing's disease. A new MRI was negative. Bilateral inferior petrosal sinus sampling showed significant pituitary-to-peripheral ratio and, in May 2010, the patient underwent exploratory pituitary surgery with evidence of a 1-2-mm white-coloured midline area compatible with pituitary adenoma that was surgically removed. Post-operatively, the patient's clinical conditions improved with onset of secondary hypoadrenalism. The histologic examination confirmed a pituitary adenoma (immunostaining was found to be positive for ACTH and negative for prolactin). We report the case of an ACTH-producing microadenoma metachronous to a prolactin secreting microadenoma although not confirmed histologically, shrunk by medical treatment. A review of data in the literature regarding double or multiple pituitary adenomas has also been done.
Collapse
Affiliation(s)
- D Iacovazzo
- Department of Endocrinology, Catholic University, Policlinico A. Gemelli, Largo A. Gemelli, 8, 00168, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Bianchi A, De Marinis L, Fusco A, Lugli F, Tartaglione L, Milardi D, Mormando M, Lassandro AP, Paragliola R, Rota CA, Della Casa S, Corsello SM, Brizi MG, Pontecorvi A. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel. J Endocrinol Invest 2011; 34:692-7. [PMID: 22067307 DOI: 10.3275/8058] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The aim of this retrospective study was to evaluate the efficacy, safety, and tolerability of lanreotide autogel given to metastatic well-differentiated (WD) neuroendocrine tumors (NET) patients observed in our Institute between 2005 and 2008. Patients with metastatic NET referred to our tertiary referral center were given lanreotide autogel 120 mg/month by deep sc injection for a period of at least 24 months. The efficacy was evaluated by the relief of disease symptoms, behavior of tumor markers and response rate in terms of time to tumor progression. Safety and tolerability were evaluated by assessing the onset of adverse events and treatment feasibility. Twenty-three patients (13 males), median age 62 yr (range 32-87) were considered for the study. All patients were affected by WD metastatic NET and had tumor progression in the last 6 months before the enrolment in the study. Median duration of response was 28 months (range 6-50 months). Fourteen patients (60.9%) showed flushing and diarrhea which improved by 85.7% and 55.6%, respectively, bronchoconstrinction and abdominal pain also ameliorated. A complete, partial or no-changed response in the tumor markers behavior was observed, respectively, in 42.9%, 22.9%, and 17.1% of cases. According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria (version 1.1), there were 2 partial regression (8.7%) and 15 stable disease (65.3%); 6 patients (26.0%) progressed. No patient complained from any severe adverse reaction. The results of our study suggest that lanreotide autogel is effective in the symptoms, biochemical markers, and tumor progression control of WD metastatic NET and confirm that the treatment is well tolerated.
Collapse
Affiliation(s)
- A Bianchi
- Department of Endocrinology, Catholic University, Policlinico Universitario A. Gemelli, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|